The University of Alabama at Birmingham

Assistant Professor

Research-Molecular Biology, Immunology

BioCryst Pharmaceuticals

Director

Responsible for preclinical, clinical, and pharmaceutical development of new drug candidates. Worked with senior management and corporate partners regarding those activities. Reported to the President and COO. Pharmaceutical development team leader and pharmacology/toxicology representative for the pharmacology and toxicology content of INDs and NDAs. Designed and directed toxicological, pharmacokinetic, toxicokinetic, and metabolism studies at BioCryst Pharmaceuticals, Inc for drug discovery and development.

BioCryst Pharmaceuticals

Executive Director, Preclinical Biology and Bioanalytical Chemistry

• Preclinical, clinical, and pharmaceutical development
• Pharmaceutical development program management and
pharmacology/toxicology representative
• Pharmaceutical development: oral, intravenous,
intramuscular, and subcutaneous drug products
• Development and validation of bioanalytical assays

Takeda Global Research and Development

Principal Toxicologist

• Preclinical safety and efficacy for new molecular entities
• Investigator Brochures, INDs, NDAs (eCTD, Toxicology)

Jefferson State Community College

Instructor

My responsibilities included microbiology and biology lectures and labs.

Synthesis and PK/PD Evaluation of the Forodesine HCl Analog BCX-3040

Nucleosides and Nucleotides

Synthesis and PK/PD Evaluation of the Forodesine HCl Analog BCX-3040

Nucleosides and Nucleotides

Purine Nucleoside Phaosphorylase Inhibitor BCX-1777 (Immunocillin-H)- A Novel and Potent Immunosuppresive Agent

International Immunopharmacolgy

Synthesis and PK/PD Evaluation of the Forodesine HCl Analog BCX-3040

Nucleosides and Nucleotides

Purine Nucleoside Phaosphorylase Inhibitor BCX-1777 (Immunocillin-H)- A Novel and Potent Immunosuppresive Agent

International Immunopharmacolgy

Discovery of highly potent small molecule kallikrein inhibitors.

Medicinal Chemistry

Synthesis and PK/PD Evaluation of the Forodesine HCl Analog BCX-3040

Nucleosides and Nucleotides

Purine Nucleoside Phaosphorylase Inhibitor BCX-1777 (Immunocillin-H)- A Novel and Potent Immunosuppresive Agent

International Immunopharmacolgy

Discovery of highly potent small molecule kallikrein inhibitors.

Medicinal Chemistry

Purine Nucleoside Phosphorylase Inhibitors in T-cell Malignancies

Current Opinion in Drug Discovery and Development

Synthesis and PK/PD Evaluation of the Forodesine HCl Analog BCX-3040

Nucleosides and Nucleotides

Purine Nucleoside Phaosphorylase Inhibitor BCX-1777 (Immunocillin-H)- A Novel and Potent Immunosuppresive Agent

International Immunopharmacolgy

Discovery of highly potent small molecule kallikrein inhibitors.

Medicinal Chemistry

Purine Nucleoside Phosphorylase Inhibitors in T-cell Malignancies

Current Opinion in Drug Discovery and Development

Phase II and pharmacodynamic study of oral forodesine in patients with advanced and/or fludarabine-treated chronic lymphocytic leukemia

Blood

Synthesis and PK/PD Evaluation of the Forodesine HCl Analog BCX-3040

Nucleosides and Nucleotides

Purine Nucleoside Phaosphorylase Inhibitor BCX-1777 (Immunocillin-H)- A Novel and Potent Immunosuppresive Agent

International Immunopharmacolgy

Discovery of highly potent small molecule kallikrein inhibitors.

Medicinal Chemistry

Purine Nucleoside Phosphorylase Inhibitors in T-cell Malignancies

Current Opinion in Drug Discovery and Development

Phase II and pharmacodynamic study of oral forodesine in patients with advanced and/or fludarabine-treated chronic lymphocytic leukemia

Blood

A proof-of principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor BCX-1777

Blood

Synthesis and PK/PD Evaluation of the Forodesine HCl Analog BCX-3040

Nucleosides and Nucleotides

Purine Nucleoside Phaosphorylase Inhibitor BCX-1777 (Immunocillin-H)- A Novel and Potent Immunosuppresive Agent

International Immunopharmacolgy

Discovery of highly potent small molecule kallikrein inhibitors.

Medicinal Chemistry

Purine Nucleoside Phosphorylase Inhibitors in T-cell Malignancies

Current Opinion in Drug Discovery and Development

Phase II and pharmacodynamic study of oral forodesine in patients with advanced and/or fludarabine-treated chronic lymphocytic leukemia

Blood

A proof-of principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor BCX-1777

Blood

The Arthus Reaction in Rodents: Species-Specific Requirement of Complement

Journal of Immunology

Synthesis and PK/PD Evaluation of the Forodesine HCl Analog BCX-3040

Nucleosides and Nucleotides

Purine Nucleoside Phaosphorylase Inhibitor BCX-1777 (Immunocillin-H)- A Novel and Potent Immunosuppresive Agent

International Immunopharmacolgy

Discovery of highly potent small molecule kallikrein inhibitors.

Medicinal Chemistry

Purine Nucleoside Phosphorylase Inhibitors in T-cell Malignancies

Current Opinion in Drug Discovery and Development

Phase II and pharmacodynamic study of oral forodesine in patients with advanced and/or fludarabine-treated chronic lymphocytic leukemia

Blood

A proof-of principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor BCX-1777

Blood

The Arthus Reaction in Rodents: Species-Specific Requirement of Complement

Journal of Immunology

Intravenous and Oral Pharmacokinetic Study of BCX-1777, a Novel Purine Nucleoside Phosphorylase Transition-State Inhibitor.In Vivo Effects on Blood 2’-Deoxyguanosine in Primates

International Immunopharmacology

Synthesis and PK/PD Evaluation of the Forodesine HCl Analog BCX-3040

Nucleosides and Nucleotides

Purine Nucleoside Phaosphorylase Inhibitor BCX-1777 (Immunocillin-H)- A Novel and Potent Immunosuppresive Agent

International Immunopharmacolgy

Discovery of highly potent small molecule kallikrein inhibitors.

Medicinal Chemistry

Purine Nucleoside Phosphorylase Inhibitors in T-cell Malignancies

Current Opinion in Drug Discovery and Development

Phase II and pharmacodynamic study of oral forodesine in patients with advanced and/or fludarabine-treated chronic lymphocytic leukemia

Blood

A proof-of principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor BCX-1777

Blood

The Arthus Reaction in Rodents: Species-Specific Requirement of Complement

Journal of Immunology

Intravenous and Oral Pharmacokinetic Study of BCX-1777, a Novel Purine Nucleoside Phosphorylase Transition-State Inhibitor.In Vivo Effects on Blood 2’-Deoxyguanosine in Primates

International Immunopharmacology

Injectable peramivir mitigates disease and promotes survival in ferrets and mice infected with the highly virulent H5N1 influenza virus isolate A/Vietnam/1203/04.

Virology

Synthesis and PK/PD Evaluation of the Forodesine HCl Analog BCX-3040

Nucleosides and Nucleotides

Purine Nucleoside Phaosphorylase Inhibitor BCX-1777 (Immunocillin-H)- A Novel and Potent Immunosuppresive Agent

International Immunopharmacolgy

Discovery of highly potent small molecule kallikrein inhibitors.

Medicinal Chemistry

Purine Nucleoside Phosphorylase Inhibitors in T-cell Malignancies

Current Opinion in Drug Discovery and Development

Phase II and pharmacodynamic study of oral forodesine in patients with advanced and/or fludarabine-treated chronic lymphocytic leukemia

Blood

A proof-of principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor BCX-1777

Blood

The Arthus Reaction in Rodents: Species-Specific Requirement of Complement

Journal of Immunology

Intravenous and Oral Pharmacokinetic Study of BCX-1777, a Novel Purine Nucleoside Phosphorylase Transition-State Inhibitor.In Vivo Effects on Blood 2’-Deoxyguanosine in Primates

International Immunopharmacology

Injectable peramivir mitigates disease and promotes survival in ferrets and mice infected with the highly virulent H5N1 influenza virus isolate A/Vietnam/1203/04.

Virology

A Novel Series of Potent and Selective Small Molecule Inhibitors of the Complement Component C1s

Bioorganic & Medicinal Chemistry Letters